Table 2.

Discovery stage, validation stage and combined results for the novel 11q23.3 locus associated with IHPS.

chr	SNP	Position (bp)	Alleles			Frequency		Number		Odds Ratio (95% CI)	I2
			Eff	Alt	Sample Set	Cases	Controls	Cases	Controls		P value	(95% CI)	Het P
11	rs12721025	116706047	A	G	Discovery	0.0911	0.0569	1001	2371	1.83 (1.47–2.28)	1.0×10−7
					Denmark	0.0741	0.0582	789	876	1.30 (0.98–1.70)	0.06
					Sweden	0.0820	0.0634	128	733	1.32 (0.81–2.16)	0.27
					U.S.	0.0860	0.0538	738	697	1.66 (1.23–2.33)	7.4×10−4
					Combined			2656	4677	1.59 (1.38–1.83)	1.9×10−10	31 (0–75)	0.23
11	rs77349713	116765476	C	T	Discovery	0.0896	0.0533	1001	2371	1.76 (1.43–2.16)	1.1×10−7
					Denmark	0.0713	0.0554	793	876	1.31 (0.99–1.73)	0.06
					Sweden	0.0930	0.0760	129	730	1.25 (0.78–1.98)	0.35
					U.S.	0.0867	0.0603	738	697	1.48 (1.11–1.97)	6.7×10−3
					Combined			2661	4674	1.53 (1.33–1.75)	1.2×10−9	21 (0–90)	0.28
11	rs150758276	117085874	C	G	Discovery	0.0392	0.0188	1001	2371	2.94 (2.00–4.31)	4.0×10−8
					Denmark	0.0269	0.0201	781	872	1.35 (0.86–2.12)	0.19
					Sweden	0.0310	0.0236	129	741	1.32 (0.61–2.89)	0.48
					U.S.	0.0373	0.0244	738	697	1.55 (1.00–2.39)	0.05
					Combined			2649	4681	1.86 (1.48–2.35)	1.4×10−7	66 (50–88)	0.03

Eff, effect allele; Alt, alternative allele; Frequency, effect allele frequency; CI, confidence interval; I², heterogeneity estimate; Het P, P value for Cochran’s Q test of heterogeneity.